National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "3 The Framework." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
94
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

BOX 3-1
Safety Monograph

  1. DescriptIon of the Ingredient

    • Constituents as appropriate: chemical classification and structure; for a botanical ingredient, genus, species, part of plant; for an animal ingredient, genus, species, part of body

    • Description of individual components, alternative forms or secondary constituents

    • Descriptions of different dietary supplement preparations, how they may differ in constituents, and amounts ingested in ordinary use

  1. Safety Information (in narrative form, referencing data tables)

    • Human safety data (serious and nonserious adverse effects): historical use, if applicable; adverse effects from clinical trials, clinical case reports, and adverse event reports; interactions (i.e., drug interactions); consequences of unusually large intake and/or chronic cumulative use

    • Animal studies

    • In vitro studies

    • Biological activity of related substances (structurally, taxonomically, and functionally related)

  1. Other Relevant Information (if known and applicable)

    • Sources of ingredient

    • Conditions of use suggested or recommended in labeling or other marketing material

    • Cautions about use from historical use, labeling, or other marketing material

    • Usage patterns (prevalence of use in the general population, use by vulnerable groups)

    • Information on regulatory actions, including those of regulatory agencies in other countries

    • Available information on physiological and biochemical aspects (bioavailability, distribution, metabolism)

  1. Summary and Conclusions

    • Summary

    • Conclusions about the safety of the ingredient, based on the strength of the scientific evidence

    • Unresolved issues and uncertainties in the available data

    • Data gaps and future research recommended

  1. Literature Search Strategy

  2. Literature Cited

  3. Tables of Key Data Evaluated

Page
94
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)